Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
or

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
163.30 x 5 163.65 x 1
Post-market by (Cboe BZX)
163.63 +0.61 (+0.37%) 03/21/25 [NYSE]
163.30 x 5 163.65 x 1
Post-market 163.63 unch (unch) 19:33 ET
Quote Overview for Fri, Mar 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
162.48
Day High
164.13
Open 163.00
Previous Close 163.02 163.02
Volume 17,047,100 17,047,100
Avg Vol 9,669,310 9,669,310
Stochastic %K 23.77% 23.77%
Weighted Alpha +7.85 +7.85
5-Day Change +0.82 (+0.50%) +0.82 (+0.50%)
52-Week Range 140.68 - 169.99 140.68 - 169.99
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 394,323,456
  • Shares Outstanding, K 2,409,848
  • Annual Sales, $ 88,821 M
  • Annual Income, $ 14,066 M
  • EBIT $ 14,023 M
  • EBITDA $ 21,362 M
  • 60-Month Beta 0.47
  • Price/Sales 4.42
  • Price/Cash Flow 12.42
  • Price/Book 5.49

Options Overview Details

View History
  • Implied Volatility 18.51% ( +0.58%)
  • Historical Volatility 15.31%
  • IV Percentile 75%
  • IV Rank 53.94%
  • IV High 23.61% on 01/10/25
  • IV Low 12.53% on 05/09/24
  • Put/Call Vol Ratio 0.45
  • Today's Volume 26,392
  • Volume Avg (30-Day) 39,473
  • Put/Call OI Ratio 0.61
  • Today's Open Interest 497,237
  • Open Int (30-Day) 449,357

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 2.59
  • Number of Estimates 7
  • High Estimate 2.66
  • Low Estimate 2.51
  • Prior Year 2.71
  • Growth Rate Est. (year over year) -4.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
161.10 +1.57%
on 03/14/25
Period Open: 162.30
169.99 -3.74%
on 03/04/25
+1.33 (+0.82%)
since 02/21/25
3-Month
140.68 +16.31%
on 01/10/25
Period Open: 144.47
169.99 -3.74%
on 03/04/25
+19.16 (+13.26%)
since 12/20/24
52-Week
140.68 +16.31%
on 01/10/25
Period Open: 155.75
169.99 -3.74%
on 03/04/25
+7.88 (+5.06%)
since 03/21/24

Most Recent Stories

More News
Stock market today: Wall Street closes higher, snapping a 4-week losing streak

U.S. stocks shook off a weak start and ended slightly higher, enough to break a four-week losing streak

NVDA : 117.70 (-0.70%)
AAPL : 218.27 (+1.95%)
$SPX : 5,667.56 (+0.08%)
JNJ : 163.63 (+0.37%)
MU : 94.72 (-8.04%)
NKE : 67.94 (-5.46%)
$IUXX : 19,753.97 (+0.39%)
DAL : 46.77 (-0.38%)
MSFT : 391.26 (+1.14%)
LMT : 439.70 (-5.79%)
DRI : 199.93 (+0.46%)
$DOWI : 41,985.35 (+0.08%)
Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals

This week, the FDA approved J&J’s JNJ Tremfya for its second inflammatory bowel disease (“IBD”) condition, Crohn’s disease (“CD”), and Novartis’ NVS Fabhalta for its third indication, C3...

AZN : 74.93 (-2.08%)
JNJ : 163.63 (+0.37%)
NVS : 112.13 (-0.95%)
PFE : 26.28 (+0.34%)
SNY : 56.90 (-1.54%)
J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's Disease

Johnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel disease (IBD) condition — moderately to severely active Crohn’s disease...

JNJ : 163.63 (+0.37%)
MRK : 93.11 (-1.71%)
LLY : 837.57 (-0.59%)
ABBV : 210.01 (-0.92%)
Johnson & Johnson plans $55 billion in US investments over the next four years

Johnson & Johnson says it will invest more than $55 billion within the United States over the next four years, including four new manufacturing plants

AAPL : 218.27 (+1.95%)
$SPX : 5,667.56 (+0.08%)
JNJ : 163.63 (+0.37%)
$DOWI : 41,985.35 (+0.08%)
$IUXX : 19,753.97 (+0.39%)
Pfizer Sells Remaining 7.3% Stake in Haleon for Around 3.3B

Pfizer PFE has sold off its remaining stake in consumer health company Haleon HLN to institutional investors and Haleon itself for around $3.3 billion. Pfizer sold its 7.3% stake in Haleon, or approximately...

JNJ : 163.63 (+0.37%)
HLN : 10.28 (-1.06%)
GSK : 39.24 (-0.43%)
PFE : 26.28 (+0.34%)
Honeywell Isn't Going to Let a Little Breakup Ruin Its Growth Plans

Investors are usually happy when a company can pull off one big goal and do it well. So Wall Street was almost certainly expecting Honeywell (NASDAQ: HON) to focus all of its attention in the immediate...

HON : 210.12 (-0.37%)
JNJ : 163.63 (+0.37%)
GEHC : 81.49 (-0.39%)
KVUE : 23.31 (-0.34%)
GEV : 333.87 (-0.88%)
GE : 204.13 (+0.10%)
Got $300? Buy These 3 Top Dividend Stocks and Never Look Back.

Some companies are just better than others at paying dividends. They offer higher-yielding payouts that they steadily increase in good times and bad. They're the type of companies you can buy and forget....

BIPC : 35.36 (-0.70%)
JNJ : 163.63 (+0.37%)
BIP : 28.72 (-0.10%)
O : 55.80 (-1.17%)
Resilient Investing: 3 Stocks Built to Weather Market Volatility

Resilient companies with strong financials and diverse revenue in healthcare, technology, and essential services can offer stability in volatile markets.

MSFT : 391.26 (+1.14%)
WM : 224.91 (-0.88%)
JNJ : 163.63 (+0.37%)
The S&P 500 Is in Correction Territory: 4 Surefire Stocks to Buy Right Now

Amazing deals abound within Wall Street's benchmark index.

GOOGL : 163.99 (+0.73%)
GOOG : 166.25 (+0.73%)
AZO : 3,606.34 (+0.92%)
$SPX : 5,667.56 (+0.08%)
JNJ : 163.63 (+0.37%)
NEE : 70.88 (-0.38%)
Kroger CEO Shake-Up

In this podcast, Motley Fool analysts Nick Sciple and Karl Theil join hosts Ricky Mulvey and Mary Long to discuss:

TGT : 104.06 (-0.13%)
GOOGL : 163.99 (+0.73%)
NVDA : 117.70 (-0.70%)
GOOG : 166.25 (+0.73%)
KR : 65.40 (+1.05%)
JNJ : 163.63 (+0.37%)
TPB : 57.65 (-0.15%)
ACI : 21.14 (-0.61%)
ANF : 79.38 (-3.61%)
MDT : 90.33 (-0.98%)
ISRG : 492.49 (+0.14%)
VINP : 10.34 (+0.10%)
Zimmer Biomet Focuses on Innovation Amid Growing Competition

Zimmer Biomet Holdings, Inc. ZBH is participating in the ongoing American Academy of Orthopaedic Surgeons (AAOS) 2025 Annual Meeting in San Diego, from March 10-14. Here, the company is highlighting advancements...

ZBH : 110.73 (-0.94%)
SNN : 28.13 (-1.16%)
SYK : 371.11 (-0.83%)
JNJ : 163.63 (+0.37%)
Cool, Calm, and Collected: 2 Dividend ETFs to Buy During the S&P 500 Sell-Off

A stock market correction occurs when a major index falls 10% off its highs. The S&P 500 (SNPINDEX: ^GSPC) hit that level Thursday, falling almost 1.4% to end the day 10.1% below its all-time high set...

COMP : 9.39 (+3.30%)
$NASX : 17,784.05 (+0.52%)
KO : 68.67 (-1.49%)
VIG : 194.17 (-0.17%)
$SPX : 5,667.56 (+0.08%)
JNJ : 163.63 (+0.37%)
VYM : 128.40 (-0.42%)
WMT : 85.98 (+0.47%)
Generate Passive Income From This Low-Cost Vanguard ETF That Is Crushing the S&P 500 in 2025

Investors typically turn to dividend-paying stocks and exchange-traded funds (ETFs) to boost their passive income streams so that their returns aren't solely tied to stock price gains. But so far this...

GOOGL : 163.99 (+0.73%)
AAPL : 218.27 (+1.95%)
AVGO : 191.66 (+0.59%)
JPM : 241.63 (+1.10%)
JNJ : 163.63 (+0.37%)
BRK.TO : 39.08 (-1.34%)
UNH : 516.85 (+1.09%)
COMP : 9.39 (+3.30%)
MSFT : 391.26 (+1.14%)
TSLA : 248.71 (+5.27%)
V : 335.66 (-1.13%)
LLY : 837.57 (-0.59%)
Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks

Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks

SUPN : 32.15 (-0.53%)
JNJ : 163.63 (+0.37%)
ZTS : 163.03 (-0.08%)
LLY : 837.57 (-0.59%)
PFE : 26.28 (+0.34%)
ISRG Stock Price Falls to 200-DMA: Should You Buy, Hold or Sell?

Shares of Intuitive Surgical ISRG have declined 16.5% in the past month, with the price currently trading around its 200-day moving average (200-DMA). The price corrected after touching its all-time high...

JNJ : 163.63 (+0.37%)
MDT : 90.33 (-0.98%)
ISRG : 492.49 (+0.14%)
Vanguard High Dividend Yield ETF vs Vanguard Dividend Appreciation ETF: Which Is Best for You?

Vanguard has some excellent dividend ETFs, but they are right for different investors.

AAPL : 218.27 (+1.95%)
AVGO : 191.66 (+0.59%)
BAC : 42.47 (-0.02%)
JPM : 241.63 (+1.10%)
JNJ : 163.63 (+0.37%)
VYM : 128.40 (-0.42%)
ABBV : 210.01 (-0.92%)
UNH : 516.85 (+1.09%)
MSFT : 391.26 (+1.14%)
COST : 909.26 (+1.55%)
MA : 535.69 (-0.13%)
VIG : 194.17 (-0.17%)
Tariffs Turmoil: Weather the Storm With These Dividend Stocks

The financial landscape is currently dominated by escalating trade tensions, with President Trump’s recent tariff policies introducing significant uncertainty. Trump’s tariffs have rattled markets,...

DG : 83.66 (+2.44%)
KO : 68.67 (-1.49%)
AWK : 141.13 (-0.48%)
JNJ : 163.63 (+0.37%)
SDY : 134.20 (-0.66%)
SCHD : 27.76 (-0.68%)
PM : 151.48 (-0.65%)
O : 55.80 (-1.17%)
WMT : 85.98 (+0.47%)
Are High-Yield Dividend Stocks Best for Income-Focused Investors?

When selecting dividend-paying stocks, one of the first things that investors look at is, of course, the annual yield.But are high-yield stocks always the best route for income-focused investors? Let’s...

KO : 68.67 (-1.49%)
JNJ : 163.63 (+0.37%)
PG : 166.69 (-0.51%)
2025 March Market Cap Showdown: Andy Cross vs. Matt Argersinger

It's time for another Market Cap Game Show. To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center . To get started investing, check out our beginner's guide to investing...

GOOGL : 163.99 (+0.73%)
ROKU : 78.29 (+6.06%)
AAPL : 218.27 (+1.95%)
DDD : 2.58 (+0.78%)
DDOG : 105.03 (+1.80%)
JNJ : 163.63 (+0.37%)
RXO : 18.59 (-1.85%)
QXO : 12.67 (-5.66%)
UA : 6.10 (unch)
DUOL : 309.30 (+1.02%)
FICO : 1,853.29 (-0.01%)
SBUX : 97.07 (-2.23%)
Zacks Investment Ideas feature highlights: Gilead Sciences and Johnson & Johnson

For Immediate ReleaseChicago, IL – March 10, 2025– Today, Zacks Investment Ideas feature highlights Gilead Sciences GILD and Johnson & Johnson JNJ.Buy Gilead Sciences (GILD) Stock at 52-Week Highs?Medical...

JNJ : 163.63 (+0.37%)
GILD : 107.08 (+1.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among...

See More

Key Turning Points

3rd Resistance Point 166.00
2nd Resistance Point 165.06
1st Resistance Point 164.35
Last Price 163.63
1st Support Level 162.70
2nd Support Level 161.76
3rd Support Level 161.05

See More

52-Week High 169.99
Last Price 163.63
Fibonacci 61.8% 158.79
Fibonacci 50% 155.33
Fibonacci 38.2% 151.88
52-Week Low 140.68

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals